Introduction {#s1}
============

Diffuse low-grade gliomas are the most common primary malignancies in adults and include astrocytomas, oligodendrogliomas, and oligoastrocytomas ([@B1]). Different histological subtypes of glioma were undistinguishable; however, large differences in clinical behavior and response to therapy suggest that difference among the histological types is crucial ([@B17]). Even within each subtype, there are large differences in clinical performance among individual patients. Surgery resection is the primary therapeutic method for low-grade gliomas, but the outcomes are less than satisfactory because of the highly infiltrative nature of glioma, and the presence of residual tumor tissue results in recurrence and malignant progression ([@B6]). The prognosis of patients with relatively low-grade glioma varies widely, with some patients living for more than 5 years, while others survive less than 1 year ([@B3]). A more precise method of predicting the outcomes of relatively low-grade glioma is urgently needed to be developed.

Metabolic reprogramming is a central hallmark of cancer. Dysregulation of metabolism-related genes leads to cellular transformation and tumor progression. [@B21] revealed differences in the central metabolic pathways in solid tumors and noted that cancer cells require a large amount of glucose to maintain a high rate of glycolysis even in the presence of adequate oxygen and that they convert a majority of that glucose into lactic acid (the Warburg effect). More recently, it has been recognized that the "Warburg effect" contains a similarly increased utilization of glutamine ([@B14]). Previous studies have detected some variations in the genes, such as *IDH1/2*, *GLUT1*, and *GLUT3*, involved in tumor metabolism in gliomas ([@B22]; [@B20]; [@B10]). High-throughput sequencing has substantially advanced the understanding of the metabolic changes in low-grade gliomas by detecting changes in metabolism-associated genes ([@B2]). Profiling holistic gene expression not only facilitates the investigation of subgroups with low-grade glioma but also enables the identification of the predictors of overall survival (OS) ([@B4]). Which pattern of expression of metabolism-associated genes in tumor tissue contributes to glioma is not well understood. The Cancer Genome Atlas (TCGA) provided a standardized gene expression dataset for the study of the expression pattern of metabolism-related genes, which enables the investigation of correlations between clinical manifestations and carbon metabolism--associated genes in glioma ([@B19]; [@B16]).

In this study, we investigated the expression patterns of central carbon metabolism--associated genes in adult patients with diffuse low-grade glioma, including astrocytoma, oligodendroglioma, and oligoastrocytoma. Moreover, we respectively detected the prognostic roles of individual gene and the multiple-gene combination. These results will facilitate an integral understanding of the metabolic alterations in glioma and provide a novel perspective to manage and treat this lethal cancer.

Methods {#s2}
=======

Samples and Database {#s2_1}
--------------------

We obtained transcriptome data and the corresponding clinical data of 514 relatively low-grade glioma patients from TCGA from the cBioPortal for Cancer Genomics (<http://cbioportal.org>) ([@B8]). We filtered the data based on whether the mRNA *z*-score data, histological diagnosis, and OS data were comprehensive. Collectively, the studied dataset included 194 astrocytoma samples, 130 oligoastrocytoma samples, and 190 oligodendroglioma samples.

Central carbon metabolism--related genes in the cancer-associated gene panel (hsa05230) were derived from the KEGG pathway database (<http://www.kegg.jp/kegg/>), as previously described ([@B9]). In total, 65 central carbon metabolism--associated genes were listed; however, transcriptome information was missing for *MYC* and *HKDC1*, and the remaining 63 candidate genes were included after filtration. The gene expression levels were calculated from the mRNA *z* scores and compared to the expression distribution of each gene from tumors that were diploid for the genes in 514 patients with glioma (RNA-Seq V2 RSEM), based on TCGA data.

Bioinformatics {#s2_2}
--------------

A cluster analysis of the 63 genes expressed in each histological type was used to distinguish samples based on gene expression patterns. Samples with different gene expression patterns were identified from the whole dataset. The transcriptional levels were shown as mRNA *z* scores and clustered using the hierarchical clustering algorithm in the Gene Cluster 3.0 program ([@B5]). The cluster heat map and pattern according to tumor stage were generated with the Java Treeview program ([@B15]).

Prognostic Implication Analyses {#s2_3}
-------------------------------

To investigate the prognostic role of the cancer metabolism--associated genes, we used GraphPad Prism 6 for Windows (GraphPad Software, Inc., CA, US; version 6.01, 2012) to perform comparisons of the overall survivals in different clusters. Additionally, an analysis of the difference in OS between the cohorts with low and high expression levels of differentially expressed genes was conducted with GraphPad Prism 6.

Statistical Analysis {#s2_4}
--------------------

Survival curves were plotted according to the Kaplan--Meier method and compared using the log-rank test in GraphPad Prism 6. Associations between clinical characteristics and the variables used to determine the clusters of patients were analyzed by Fisher exact test and the Pearson/Spearman correlation. Differences in gene expression levels between clusters were analyzed by analysis of variance. Correlations between variable were determined by regression analyses. All tests were performed with SPSS 19.0 (IBM, Inc., NY, US). *P* \< 0.05 was considered statistically significant.

Results {#s3}
=======

Expression Profile of Central Carbon Metabolism--Associated Genes in Diffuse Gliomas {#s3_1}
------------------------------------------------------------------------------------

To investigate central carbon metabolism programming in diffuse gliomas, we first examined the transcriptional distributions of carbon metabolism--associated genes. In total, 63 genes that have been widely reported to be key players in metabolic reprogramming were included ([@B18]). The patients with diffuse glioma were sorted by differences in the gene expression according to the RNA-Seq data. Following filtration, 514 patients with survival data were included in the cluster analysis ([**Figure 1A**](#f1){ref-type="fig"}). The preliminary analysis showed that there were two clusters, and strikingly, the 101 patients in cluster 1 had much worse prognoses than the patients in cluster 2 (OS of 48.65 vs 105.12 months, *P* \< 0.0001) ([**Figure 1B**](#f1){ref-type="fig"}, [**Table 1**](#T1){ref-type="table"}). Between the two clusters, there was a significant difference in the expression levels (*P* \< 0.05) of 49 genes ([**Figure 1C**](#f1){ref-type="fig"}). A comparison of the clinical characteristics of clusters 1 and 2 showed that the parameters of histological diagnoses, tumor grade, tumor site, and age were vastly different between the two clusters (*P* \< 0.001), as shown in [**Table 2**](#T2){ref-type="table"}.

![The expression profile of central carbon metabolism--associated genes in glioma patients. **(A)** In total, 514 patients were primarily divided into two clusters. The expression values of 63 genes corresponding to the individual patient were arrayed in the columns according to the expression affinity. Patients with similar gene expression patterns were clustered and grouped using the hierarchical clustering algorithm and arrayed in the rows. **(B)** The patients in cluster 1 had much worse prognoses than the patients in cluster 2, of which overall survival (OS) was 48.65 months compared to 105.12 months. **(C)** There were 49 genes that showed a significant difference in the expression levels between the two clusters *P* \< 0.05. **(D)** The studied cohort was further subdivided into four subclusters, among which the subcluster 1 was with the worst OS and subcluster 4 showed the most favorable outcome. **(E)** The differential expression analysis revealed that 52 metabolism-associated genes were significantly different between subcluster 1 and subcluster 4.](fgene-10-00831-g001){#f1}

###### 

Overall survival differences of each cluster.

                    Cluster   Significance *(P)*   
  ----------------- --------- -------------------- ----------
  Number            158       356                  \<0.0001
  Median survival   48.65     105.12               

###### 

Characteristics of glioma patients in clustered groups 1 and 2.

  --------------------------------------------------------------------------------------------
  Clinical features\                        Cluster       Total   *P*         
  ----------------------------------------- ------------- ------- ----- ----- ----------------
  Histological diagnosis                    Astrocytoma   92      102   194   2.96E−10\*\*\*

  Oligoastrocytoma                          34            96      130         

  Oligodendroglioma                         32            158     190         

  Grade                                     Unknown       0       1     1     \<0.001\*\*\*

  G2                                        52            196     248         

  G3                                        106           159     265         

  Age                                       ≤41           53      215   268   1.37E−8\*\*\*

  \>41                                      105           141     246         

  Tumor site                                Unknown       0       1     1     \<0.001\*\*\*

  Posterior fossa, brain stem               1             0       1           

  Posterior fossa, cerebellum               2             0       2           

  Supratentorial, frontal lobe              73            229     302         

  Supratentorial, not otherwise specified   7             1       8           

  Supratentorial, occipital lobe            0             8       8           

  Supratentorial, parietal lobe             18            28      46          

  Supratentorial, temporal lobe             57            89      146         

  Laterality                                Unknown       1       4     5     0.412

  Left                                      79            171     250         

  Midline                                   4             3       7           

  Right                                     74            178     252         

  Supratentorial localization               Unknown       7       22    29    0.853

  Cerebral cortex                           43            98      141         

  Deep gray                                 1             2       3           

  Not listed in medical Record              73            149     222         

  White matter                              34            85      119         

  Sex                                       Female        74      155   229   0.275

  Male                                      84            201     285         

  History neoadjuvant                       No            158     353   511   0.719

  Yes                                       0             3       3           
  --------------------------------------------------------------------------------------------

\*\*\*P \< 0.001.

To detect the subtler differences among further stratified cohorts, we subdivided the 514 patients into four subclusters based on the expression of the 63 genes. We detected that extreme differences in prognosis were shown among those subclusters (*P* \< 0.0001) ([**Figure 1D**](#f1){ref-type="fig"}, [**Table 3**](#T3){ref-type="table"}). Subcluster 1 was associated with the worst OS, while subcluster 4 showed a much favorable outcome than other subclusters ([**Figure 1D**](#f1){ref-type="fig"}). Comparison of the gene expression variations revealed that the expression levels of 52 metabolism-associated genes were significantly different between the two prognostic-discrepant cohorts ([**Figure 1E**](#f1){ref-type="fig"}). Additionally, we compared the clinical characteristics of the subclusters. Similar with the previous result, clear significant differences were found with regard to the parameters of histological diagnoses, tumor grade, tumor site, and age (*P* \< 0.001) ([**Table 4**](#T4){ref-type="table"}).

###### 

Overall survival differences of each subcluster

                    Subcluster   Significance *(P)*                    
  ----------------- ------------ -------------------- ------- -------- ----------
  Number            101          57                   123     233      \<0.0001
  Median survival   24.38        62.12                87.39   130.68   

###### 

Characteristics of glioma patients in subdivided clusters.

  Clinical features                         Subcluster    Total   *P*                     
  ----------------------------------------- ------------- ------- ----- ----- ----- ----- ----------------
  Histological diagnosis                    Astrocytoma   67      25    60    42    194   5.94E−21\*\*\*
  Oligoastrocytoma                          19            15      40    56    130         
  Oligodendroglioma                         15            17      23    135   190         
  Grade                                     Unknown       0       0     0     1     1     3.88E−08\*\*\*
  G2                                        20            32      60    136   248         
  G3                                        81            25      63    96    265         
  Age                                       ≤41           32      21    84    131   268   5.32E−8\*\*\*
  \>41                                      69            36      39    102   246         
  Tumor site                                Unknown       0       0     0     1     1     \<0.001\*\*\*
  Posterior fossa, brain stem               1             0       0     0     1           
  Posterior fossa, cerebellum               2             0       0     0     2           
  Supratentorial, frontal lobe              40            33      71    158   302         
  Supratentorial, not otherwise specified   4             3       0     1     8           
  Supratentorial, occipital lobe            0             0       3     5     8           
  Supratentorial, parietal lobe             11            7       15    13    46          
  Supratentorial, temporal lobe             43            14      34    55    146         
  Laterality                                Unknown       1       0     2     2     5     0.235
  Left                                      44            35      60    111   250         
  Midline                                   4             0       1     2     7           
  Right                                     52            22      60    118   252         
  Supratentorial localization               Unknown       4       3     6     16    29    0.910
  Cerebral cortex                           24            19      32    66    141         
  Deep gray                                 1             0       0     2     3           
  Not listed in medical record              50            23      55    94    222         
  White matter                              22            12      30    55    119         
  Sex\*                                     Female        45      29    47    108   229   0.357
  Male                                      56            28      76    125   285         
  History neoadjuvant                       No            100     55    119   225   499   0.453
  Yes                                       1             2       4     8     15          

\*\*\*represent P \< 0.001.

Variations in Metabolism-Associated Gene Expression Levels in Different Histological Types {#s3_2}
------------------------------------------------------------------------------------------

According to the binary comparisons among different gene expression cohorts, histological type was revealed as the variable associated with the largest differences in gene expression. We compared the OS of patients with astrocytoma, oligoastrocytoma, and oligodendroglioma, and significant differences were detected ([**Figure 2A**](#f2){ref-type="fig"}). The median survival times of patients with astrocytoma (66.12 months), oligoastrocytoma 5.12 months), and oligodendroglioma (95.5 months) were markedly distinguishing (*P* = 0.0084). Further analysis of differences in gene expression demonstrated that 45 metabolism-associated genes were differentially expressed among the histological types ([**Figure 2B**](#f2){ref-type="fig"}, [**Supplementary Table 1**](#SM1){ref-type="supplementary-material"}).

![The differences in prognoses of patients with astrocytoma, oligoastrocytoma, and oligodendroglioma were significant. **(A)** The prognoses of patients with astrocytoma, oligoastrocytoma, and oligodendroglioma were significant. **(B)** Differential expression analysis demonstrated that 45 metabolism-associated genes were discrepantly expressed among the three histological types.](fgene-10-00831-g002){#f2}

Differences in the Expression Levels of Metabolism-Associated Genes in Astrocytoma {#s3_3}
----------------------------------------------------------------------------------

The above results showed that among the histological types of glioma, astrocytoma showed the worst prognosis. To study the expression profiles of metabolism-associated genes in the poor-prognosis histological types, we grouped the patients with astrocytoma according to the metabolism-associated genes transcriptional data. Among the patients, two primary clusters that showed distinguishing median survival times of 43.99 and 73.42 months were identified (*P* = 0.0064) ([**Figures 3A, B**](#f3){ref-type="fig"}). Further, four subclusters were divided according to fine grouping. The comparison of the OS showed that the difference in prognosis was even more marked (*P* \< 0.0001) ([**Figure 3C**](#f3){ref-type="fig"}). Subcluster 2 had the worse prognosis (median of 24.9 months) than other subclusters (median of 67.41 months), *P* \< 0.0001 ([**Figure 3D**](#f3){ref-type="fig"}). We respectively detected the gene expression differences between cluster 1 versus cluster 2; among different subclusters and subcluster 2 versus the other subclusters, the results revealed that the expressions of 33 metabolism-associated genes were significantly varied ([**Figure 3E**](#f3){ref-type="fig"}).

![The expression profile of central carbon metabolism--associated genes in patients with astrocytoma. **(A)** According to expression profiling, two primary clusters and additionally four subdivided clusters were identified. The comparison of median survival between two primary clusters **(B)** and five subdivided clusters **(C)** showed significant difference. In addition, patients in subcluster 2 showed the worst prognosis comparing to other patients, *P* \< 0.0001 **(D)**. **(E)** Differential expression analysis demonstrated that 33 metabolism-associated genes were significantly variated in all contrast of clusters 1 and 2, subcluster 2 and the other subclusters, and five subclusters.](fgene-10-00831-g003){#f3}

The Prognostic Role of Metabolism-Associated Genes in Astrocytoma {#s3_4}
-----------------------------------------------------------------

We uncovered that the expression pattern of metabolism-associated genes was closely related to the prognosis of patients with astrocytoma. To investigate the effect of individual metabolism-associated gene on the prognosis of astrocytoma patients, we divided the subjects into two cohorts according to the OS: poor prognosis group and good prognosis group. We further investigated the differences in the expression levels of the metabolism-associated genes. It was detected that 11 genes, namely, *FGFR1*, *ERBB2*, *PGAM4*, *PGAM1*, *G6PD*, *RET*, *AKT3*, *PTEN*, *RAF1*, *PKM*, and *LDHA*, had significantly different expression levels between patients with poor and favorable OS times ([**Figure 4A**](#f4){ref-type="fig"}, [**Supplementary Table 2**](#SM1){ref-type="supplementary-material"}).

![The prognostic role of metabolism-associated genes in astrocytoma. **(A)** There are 11 differentially expressed genes, containing *FGFR1*, *ERBB2*, *PGAM4*, *PGAM1*, *G6PD*, *RET*, *AKT3*, *PTEN*, *RAF1*, *PKM*, and *LDHA*, which were detected to be significantly discrepant between patients with poor and favorable overall survival (OS) times. **(B)** According to study correlation of individual gene expression and survival, the expression levels of nine genes positively correlated with OS (*r* \> .2, *P* \< 0.05), and the expression levels of the other nine genes were negatively correlated with OS (*r* \< --0.2, *P* \< 0.05).](fgene-10-00831-g004){#f4}

Additionally, we detected the pertinences between the trend of metabolism-associated gene expression differential and survival variation. According to study correlation of individual gene expression and survival, positive correlations were detected between the respective expression levels of nine genes containing *PGAM1*, *PGAM4*, *RAF1*, *PDHB*, *AKT3*, *PTEN*, *PIK3R1*, *RET*, and *MAPK3* with OS (*r* \> 0.2, *P* \< 0.05); on the other hand, the expression levels of nine genes containing *EGFR*, *IDH1*, *GCK*, *PKM*, *LDHA*, *G6PD*, *TIGAR*, *ERBB2*, and *FGFR1* were detected negatively correlated to survival (*r* \< −0.2, *P* \< 0.05) ([**Table 5**](#T5){ref-type="table"}). In addition to their associations with survival, the expression levels of the genes are closely correlated between the two sets ([**Figure 4B**](#f4){ref-type="fig"}).

###### 

The correlation of overall survival (OS) of astrocytoma and expressing variation of individual gene.

  OS positively correlated genes   OS negatively correlated genes                                    
  -------------------------------- -------------------------------- ---------------- ------- ------- ---------------
  PGAM1                            0.41                             \< 0.001\*\*\*   FGFR1   −0.45   \<0.001\*\*\*
  PGAM4                            0.40                             0.001\*\*        ERBB2   −0.39   0.001\*\*
  RAF1                             0.36                             0.003\*\*        TIGAR   −0.37   0.002\*\*
  PDHB                             0.29                             0.012\*          G6PD    −0.33   0.006\*\*
  AKT3                             0.28                             0.016\*          LDHA    −0.32   0.007\*\*
  PTEN                             0.27                             0.020\*          PKM     −0.28   0.017\*
  PIK3R1                           0.26                             0.025\*          IDH1    −0.27   0.021\*
  RET                              0.25                             0.029\*          GCK     −0.27   0.018\*
  MAPK3                            0.25                             0.031\*          EGFR    −0.23   0.039\*

\*P \< 0.05; \*\*P \< 0.01; \*\*\*P \< 0.001.

To address the prognostic roles of those survival-related genes, we separately split the astrocytoma patients into two groups according to the single gene expression and additionally compared the prognosis between the two groups ([**Figure 5**](#f5){ref-type="fig"}). Except to *AKT3* and *PIK3R1*, 16 genes showed a significant association with prognosis. Patients with low expression levels of *RET* and *PGAM1* were associated with a greater hazard ratio (HR) for death than that of patients with high expression levels of *RET* and *PGAM1* (*P* \< 0.0001). In contrast, patients with high expression levels of *TIGAR*, *ERBB2*, *EGFR*, and *FGFR1* had a higher HR for death than that of patients with low expression levels of those genes (*P* \< 0.0001) ([**Table 6**](#T6){ref-type="table"}).

![The correlation of singular gene expression difference with the astrocytoma prognosis.](fgene-10-00831-g005){#f5}

###### 

The prognostic roles of single metabolism associated gene in astrocytoma.

  Gene name   Median survival (mo)   Hazard ratio   95% Confidence interval   P              
  ----------- ---------------------- -------------- ------------------------- -------------- ------------------
  RAF1        33.94                  79.93          0.331                     1.781--5.128   \<0.0001\*\*\*\*
  RET         50.82                  144.94         0.277                     2.145--6.069   \<0.0001\*\*\*\*
  EGFR        73.42                  26.91          3.007                     0.155--0.715   \<0.0001\*\*\*\*
  TIGAR       93.13                  29.11          4.276                     0.135--0.405   \<0.0001\*\*\*\*
  ERBB2       73.42                  21.29          4.301                     0.104--0.519   \<0.0001\*\*\*\*
  FGFR1       79.93                  26.91          2.776                     0.206--0.629   \<0.0001\*\*\*\*
  GCK         73.42                  29.11          2.456                     0.224--0.739   0.0004\*\*\*
  PGAM4       43.99                  93.13          0.424                     1.399--3.985   0.0007\*\*\*
  MAPK3       39.72                  93.13          0.436                     1.362--3.87    0.0011\*\*
  PGAM1       41.1                   73.42          0.409                     1.462--4.094   0.0012\*\*
  IDH1        93.13                  41.1           2.27                      0.256--0.760   0.0012\*\*
  PTEN        41.1                   79.93          0.475                     1.235--3.589   0.0027\*\*
  LDHA        62.91                  62.12          2.022                     0.288--0.850   0.0060\*\*
  G6PD        62.91                  62.12          1.946                     0.299--0.885   0.0089\*\*
  PDHB        50.82                  98.16          0.54                      1.107--3.098   0.0229\*
  PKM         62.12                  67.41          1.685                     0.345--1.022   0.0441\*
  AKT3        43.86                  67.41          0.603                     0.991--2.776   0.0526
  PIK3R1      62.12                  67.41          0.802                     0.742--2.097   0.4085

\*P \< 0.05; \*\*P \< 0.01; \*\*\*P \< 0.001; \*\*\*\*P \< 0.0001.

To evaluate the effects of differences in gene expression on the prediction of the outcome of astrocytoma, we ranked the expression data of 18 genes to construct a regression model. Based on the ranking results, four genes (*RAF1*, *AKT3*, *IDH1*, and *FGFR1*) were independent predictors of the survival status of astrocytoma patients ([**Supplementary Table S3**](#SM1){ref-type="supplementary-material"}). To integrate these four genes into a single panel, multivariate Cox regression analysis was employed to obtain the coefficient. The risk score was calculated as follows: the risk score was equal to the expression of *RAF1*∗1.801 plus the expression of *AKT3*∗1.545 plus the expression of *IDH1*∗1.569 plus the expression of *FGFR1*∗1.035 ([**Figure 6A**](#f6){ref-type="fig"}). As shown in [**Figure 6B**](#f6){ref-type="fig"}, the area under the receiver operating characteristic curve of the four-gene panel for the prediction of the long- or short-term outcomes of astrocytoma was 0.9407, with a 95% confidence interval of 0.8864 to 0.9949 and a *P* \< 0.0001.

![Four-gene panel was utilized to potentially predict the outcomes of patients with astrocytoma. **(A)** The score of the four-gene model including RAF1, AKT3, IDH1, and FGFR1 was positively correlated with overall survival and showed a linearity. **(B)** The area under the receiver operating characteristic curve of the four-gene panel for the prediction of the long- or short-term outcomes of astrocytoma was 0.9407, with a 95% confidence interval of 0.8864 to 0.9949 and *P* \< 0.0001.](fgene-10-00831-g006){#f6}

Discussion {#s4}
==========

Low-grade glioma has complicated characteristics and diverse histologic types. Although the histopathological classification of low-grade gliomas is reliable, it varies between observers and is insufficient to predict clinical outcomes ([@B13]). Recently, the molecular analysis of tumors has become a critical part of tumor classification and prognostication, and increasing evidence has suggested that defining tumor subtypes based on differences in gene expression in low-grade glioma is meaningful ([@B20]; [@B7]; [@B13]). In this study, we found that metabolism-associated gene profiling was able to define two primary clusters and four subclusters of patients with low-grade glioma regardless of histologic type. Overall survival differed between the primary clusters and subclusters. We identified 44 genes with significant differences in expression levels between the groups of patients with the worst and best prognoses ([**Figure S1**](#SM1){ref-type="supplementary-material"}). Some of those genes participate in the regulation of intracellular signal transduction, and others are involved in the metabolism of glucose and other carbohydrates. In addition to the differences in gene expression, we found that the groups had significant differences in histological types, tumor grades, tumor sites, and age. The results showed the specific expression profiles of metabolism-associated genes in patients with low-grade glioma.

Astrocytomas, oligoastrocytomas, and oligodendrogliomas are the three histologic subtypes of low-grade glioma; the subtypes have always been difficult to define according to clinical features ([@B12]). In the current dataset, patients with astrocytoma had worse prognoses than those of patients with the other two subtypes. We detected the differentially expressed genes in patients with different histological types of glioma, and 45 genes were significantly differentially expressed among the three subtypes. Moreover, 80% of those genes (35 genes) overlapped with the gene set (44 genes) that was associated with different subgroups. Specifically, we determined the expression profiles of metabolism-associated genes in astrocytomas. The results showed that 33 genes had significantly different expression levels, and those differences in expression were closely correlated with OS in patients with astrocytomas. These differences in the expression of metabolism-associated genes not only reveal metabolic differences among the histological subtypes but also suggest that there is metabolic heterogeneity within a single subtype.

In patients with astrocytomas, we identified 11 genes that varied significantly in expression between patients with poor and favorable OS. Additionally, we detected genes with expression levels that were positively and negatively associated with OS, and a correlation existed between the expression levels of these two sets of genes. According to the survival analysis, 16 genes were significantly associated with prognosis. Patients with low expression levels of *RET* and *PGAM1* and high expression levels of *TIGAR*, *ERBB2*, *EGFR*, and *FGFR1* had elevated HRs with regard to survival. The *RET* gene encodes a transmembrane receptor that is a member of the tyrosine protein kinase family of proteins. It has been reported that the mRNA levels of *RET* are elevated in astrocytoma patients with *IDH* mutations, who are known to have prolonged survival ([@B23]). *PGAM1* is involved in tumor cell glycolysis and biosynthesis, and this protein had elevated expression levels in high-grade astrocytomas ([@B11]). Increased expression of these two genes in astrocytomas might inhibit metabolic pathways crucial to the development and progression of tumors.

Low-grade glioma is one of the most malignant human diseases, with a very poor prognosis and scant available information about its biological properties. This study provided new information about the metabolism events affected by the identified genes with differential expression levels. We divided the patients into different subgroups according to their metabolism-associated gene expression patterns. The expression levels of those genes were strongly correlated with the prognosis of patients with astrocytoma, possibly because of their effect on the regulation of the biological behavior of the tumor. This study increases our understanding of the prognostic roles of central carbon metabolism--associated genes in patients with low-grade glioma.
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